Kiniksa Pharmaceuticals International, plc
KNSA
$27.65
-$0.09-0.32%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 12.44% | 9.20% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 12.44% | 9.20% | |||
| Cost of Revenue | -6.70% | 33.73% | |||
| Gross Profit | 34.86% | -10.11% | |||
| SG&A Expenses | 7.39% | -12.64% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -12.21% | 16.38% | |||
| Operating Income | 168.77% | -99.82% | |||
| Income Before Tax | 191.67% | -135.79% | |||
| Income Tax Expenses | 186.84% | -247.32% | |||
| Earnings from Continuing Operations | 196.07% | 29.98% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 196.07% | 29.98% | |||
| EBIT | 168.77% | -99.82% | |||
| EBITDA | 172.05% | -104.11% | |||
| EPS Basic | 195.61% | 30.56% | |||
| Normalized Basic EPS | 191.27% | -133.97% | |||
| EPS Diluted | 189.50% | 30.56% | |||
| Normalized Diluted EPS | 187.12% | -133.97% | |||
| Average Basic Shares Outstanding | 0.45% | 0.83% | |||
| Average Diluted Shares Outstanding | 5.29% | 0.83% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||